A Phase 2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-104 in Subjects Ages 18-75 with Primary Biliary Cholangitis Who Are Unresponsive to UDCA and/or OCA
Clinical Trial Grant
Administered By
Medicine, Gastroenterology
Awarded By
COUR Pharmaceuticals Development Company
Start Date
July 13, 2022
End Date
July 17, 2025
Administered By
Medicine, Gastroenterology
Awarded By
COUR Pharmaceuticals Development Company
Start Date
July 13, 2022
End Date
July 17, 2025